Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Cancer Science|March 4, 2008
DNA polymerase gamma inhibition by vitamin K3 induces mitochondria-mediated cytotoxicity in human cancer cellsRyohei Sasaki, Yoko Suzuki, Yuko Yonezawa, et al.International Journal of Clinical Oncology|October 30, 2020
Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2)Tomoya Yokota, Yosuke Ota, Hirofumi Fujii, et al.International Journal of Clinical Oncology|August 24, 2022
Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2)Yosuke Ota, Takeshi Kodaira, Hirofumi Fujii, et al.Journal of Medicinal Chemistry|May 8, 2009
Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitorsNobuaki Suzuki, Takayoshi Suzuki, Yosuke Ota, et al.American Journal of Physiology. Lung Cellular and Molecular Physiology|October 26, 2018
HDAC8 inhibition ameliorates pulmonary fibrosisShigeki Saito, Yan Zhuang, Takayoshi Suzuki, et al.Biochimica Et Biophysica Acta|April 15, 2009
Cell cycle arrest triggered by conjugated eicosapentaenoic acid occurs through several mechanisms including G1 checkpoint activation by induced RPA and ATR expressionYuko Kumamoto-Yonezawa, Ryohei Sasaki, Yosuke Ota, et al.Frontiers in Immunology|February 16, 2023
DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effectsYosuke Ota, Yasuhiro Nagai, Yuko Hirose, et al.Chemmedchem|January 10, 2014
Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitorsTakayoshi Suzuki, Nobusuke Muto, Masashige Bando, et al.Journal of Clinical Biochemistry and Nutrition|March 26, 2013
NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkersKiyoshi Fukuhara, Akiko Ohno, Yosuke Ota, et al.Frontiers in Oncology|February 7, 2019
A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, et al.Pageof 6